AbbVie Inc. (ABBV - Free Report) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 14.4% in the past one-month time frame.
The move came after the company announced solid top-line results from the Phase 2b study of upadacitinib. This covers the latest research on medication for eczema.
The company has not seen any estimate revisions in the past one month, while its Zacks Consensus Estimate for the current quarter has moved lower over the same time period. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
AbbVie currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative.
Investors interested in the Medical sector may consider a better-ranked stock like Merit Medical Systems, Inc. (MMSI - Free Report) , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ABBV going up? Or down? Predict to see what others think: Up or Down
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
AbbVie Inc. (ABBV - Free Report) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 14.4% in the past one-month time frame.
The move came after the company announced solid top-line results from the Phase 2b study of upadacitinib. This covers the latest research on medication for eczema.
The company has not seen any estimate revisions in the past one month, while its Zacks Consensus Estimate for the current quarter has moved lower over the same time period. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
AbbVie currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative.
Investors interested in the Medical sector may consider a better-ranked stock like Merit Medical Systems, Inc. (MMSI - Free Report) , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ABBV going up? Or down? Predict to see what others think: Up or Down
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MMSI - FREE
Get the latest research report on ABBV - FREE